Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALKS

ALKS - Alkermes PLC Stock Price, Fair Value and News

28.91USD-0.27 (-0.93%)Market Closed
Watchlist

Market Summary

USD28.91-0.27
Market Closed
-0.93%

ALKS Alerts

  • Big jump in Earnings (Y/Y)

ALKS Stock Price

View Fullscreen

ALKS RSI Chart

ALKS Valuation

Market Cap

4.8B

Price/Earnings (Trailing)

13.58

Price/Sales (Trailing)

2.9

EV/EBITDA

8.97

Price/Free Cashflow

13.67

ALKS Price/Sales (Trailing)

ALKS Profitability

EBT Margin

25.34%

Return on Equity

29.58%

Return on Assets

16.65%

Free Cashflow Yield

7.31%

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.7B

Rev. Growth (Yr)

23.89%

Rev. Growth (Qtr)

-0.91%

ALKS Earnings

Earnings (TTM)

355.8M

Earnings Growth (Yr)

499.16%

Earnings Growth (Qtr)

136.15%

Breaking Down ALKS Revenue

Last 7 days

17.8%

Last 30 days

14.1%

Last 90 days

32.8%

Trailing 12 Months

18.8%

How does ALKS drawdown profile look like?

ALKS Financial Health

Current Ratio

2.86

Debt/Equity

0.24

Debt/Cashflow

1.39

ALKS Investor Care

Shares Dilution (1Y)

1.63%

Diluted EPS (TTM)

2.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.1B1.5B1.6B1.7B
20221.2B1.2B1.1B1.1B
20211.0B1.1B1.1B1.2B
20201.2B1.2B1.2B1.0B
20191.1B1.1B1.1B1.2B
2018936.7M1.0B1.1B1.1B
2017780.7M804.4M841.5M903.4M
2016623.9M667.7M695.3M745.7M
2015649.8M647.7M640.4M628.3M
2014563.1M577.9M598.1M618.8M
2013575.5M561.9M577.8M596.3M
2012390.0M480.3M532.3M542.6M
2011186.6M219.3M242.1M331.8M
2010178.3M180.4M182.5M184.6M

Tracking the Latest Insider Buys and Sells of Alkermes PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
brown iain michael
acquired
-
-
4,680
svp, chief financial officer
Feb 20, 2024
landine michael j
acquired
-
-
5,461
svp, corp dev., alkermes, inc.
Feb 20, 2024
hopkinson craig c.
sold (taxes)
-138,943
30.39
-4,572
evp r&d, chief medical officer
Feb 20, 2024
hopkinson craig c.
acquired
-
-
10,297
evp r&d, chief medical officer
Feb 20, 2024
parisi samuel joseph
sold (taxes)
-19,480
30.39
-641
vp, finance (interim pao)
Feb 20, 2024
gaffin david joseph
acquired
-
-
7,177
evp, clo, alkermes, inc.
Feb 20, 2024
gaffin david joseph
sold (taxes)
-90,987
30.39
-2,994
evp, clo, alkermes, inc.
Feb 20, 2024
jackson blair curtis
acquired
-
-
4,680
evp, chief operating officer
Feb 20, 2024
brown iain michael
sold (taxes)
-52,422
30.39
-1,725
svp, chief financial officer
Feb 20, 2024
parisi samuel joseph
acquired
-
-
1,872
vp, finance (interim pao)

1–10 of 50

Which funds bought or sold ALKS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
Raleigh Capital Management Inc.
added
4.68
351
9,936
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
4.94
1,672,000
44,262,000
0.01%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
added
10.51
767,649
8,891,840
0.01%
Feb 15, 2024
Farther Finance Advisors, LLC
added
233
1,354
1,942
-%
Feb 15, 2024
State of Wyoming
new
-
264,418
264,418
0.05%
Feb 15, 2024
Palo Alto Investors LP
unchanged
-
-162,918
16,738,300
1.51%
Feb 15, 2024
GTS SECURITIES LLC
sold off
-100
-1,067,350
-
-%
Feb 15, 2024
Legal & General Group Plc
added
100
8,406,410
16,959,200
-%
Feb 15, 2024
Virtus Fund Advisers, LLC
unchanged
-
-721
74,038
0.46%
Feb 15, 2024
JANE STREET GROUP, LLC
added
0.97
-136
2,972,400
-%

1–10 of 46

Are Funds Buying or Selling ALKS?

Are funds buying ALKS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALKS
No. of Funds

Unveiling Alkermes PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.56%
20,955,454
SC 13G/A
Feb 08, 2024
wellington management group llp
9.13%
15,241,470
SC 13G
Jan 24, 2024
state street corp
5.60%
9,352,970
SC 13G
Jan 08, 2024
blackrock inc.
18.0%
30,021,312
SC 13G/A
Aug 24, 2023
sarissa capital management lp
997%
8,323,400
SC 13D/A
Jun 28, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 27, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 23, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 21, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 16, 2023
sarissa capital management lp
-
0
SC 13D/A

Recent SEC filings of Alkermes PLC

View All Filings
Date Filed Form Type Document
Feb 21, 2024
10-K
Annual Report
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 15, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of ALKS?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Alkermes PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
156.0B
46.5B
-3.76% -37.06%
-112.32
3.35
42.59% -114.62%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.58
2.9
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.1B
8.8B
-0.23% 18.85%
-5.25
0.35
7.79% -163.11%
2.5B
601.3M
-0.28% 70.16%
18.38
4.14
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
20.7M
84.1M
58.23% -28.98%
-0.97
0.22
2882.68% -145.15%
16.8M
111.1M
-6.33% -18.68%
-1.05
0.15
-10.43% 84.90%
2.4M
20.0M
-35.83% -91.10%
-0.17
0.12
137.71% 66.04%

Alkermes PLC News

Latest updates
AmericanBankingNEWS21 minutes ago

Alkermes PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-0.9%377,475380,938617,397287,595304,674252,357276,219278,545324,463294,141303,717251,430279,995265,012247,529246,220412,730255,243279,872223,102315,762
Costs and Expenses-41.0%198,900337,090378,204335,089325,256312,998310,676305,130322,080313,800299,296267,862310,724275,679281,190283,590422,664308,864315,795299,103315,742
  S&GA Expenses-17.0%140,570169,446205,258174,477157,541152,777150,377145,052160,408136,213139,188125,168145,778127,653132,025133,372154,453148,701155,075141,220141,227
  R&D Expenses-121.4%-20,75997,140100,78893,637104,586100,43092,87395,95398,374118,41197,47392,268112,10794,98094,22293,279198,157107,671104,435102,570108,972
EBITDA Margin57.5%0.31*0.20*0.14*-0.07*-0.07*-0.05*-0.01*0.02*0.04*0.01*0.03*0.01*---------
Interest Expenses0.8%6,0546,0065,6845,2884,7693,5522,3692,3502,4052,4372,4073,9701,8691,8112,1222,8573,1963,3853,5203,5003,478
Income Taxes-23383.2%-93,933-4002,700-6,0106,566-3,394-3,114-9,095-6462,4533,2913,7659962,3263,6737,3292,797-9831,604-3,8548,022
Earnings Before Taxes284.8%182,26047,361239,753-47,855-21,688-67,368-33,250-44,998227-26,5355,655-18,653-41,6462,192-25,758-31,325-2,557-53,861-40,386-100,252-1,691
EBT Margin85.3%0.25*0.14*0.07*-0.15*-0.15*-0.13*-0.09*-0.05*-0.03*-0.07*-0.05*-0.08*---------
Net Income136.1%112,77947,758237,065-41,845-28,254-63,974-30,136-35,903873-28,9882,364-22,418-42,642-134-29,431-38,654-5,354-52,878-41,990-96,398-9,713
Net Income Margin58.4%0.21*0.13*0.07*-0.15*-0.14*-0.11*-0.08*-0.05*-0.04*-0.08*-0.06*-0.09*---------
Free Cashflow5.8%90,20785,255206,005-28,162-8,981-9,849-12,26813,88722,36077,96426,503-53,132---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-6.3%2,1362,2792,1871,9231,9641,9421,9571,9782,0241,9951,9381,8781,9501,8771,8021,8261,8051,7581,7521,7571,825
  Current Assets1.4%1,4861,4651,3971,1101,1301,0541,0461,0151,0621,0531,0381,0061,1111,025947913962998995963983
    Cash Equivalents-29.4%457648666321292264255283338310258205273241189176204261196225267
  Inventory-3.0%18619218918518116615615515013913613412612311610910210195.0093.0090.00
  Net PPE-30.7%227328324321325326337337341341344346350355362363362341326320310
  Goodwill-10.6%83.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.00
Liabilities1.1%934924907917920899875902912899840827883792740763720690661654654
  Current Liabilities3.4%520503487493498470439462471453383366438378321340391370334328340
  Long Term Debt-100.0%-288289290290291292292293293294295272273273274274275275276276
    LT Debt, Current0%3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00
    LT Debt, Non Current-0.2%288288289290290291292292293293294295272273273274274275275276276
Shareholder's Equity-11.3%1,2031,3561,2801,0061,0441,0431,0821,0751,1131,0961,0981,0511,0671,0841,0621,0631,0851,0681,0911,1021,171
  Retained Earnings7.7%-1,343-1,456-1,504-1,741-1,699-1,671-1,607-1,576-1,541-1,541-1,512-1,515-1,492-1,450-1,450-1,420-1,381-1,376-1,323-1,281-1,185
  Additional Paid-In Capital-8.9%2,7373,0032,9762,9392,9132,8862,8582,8192,7982,7792,7492,7032,6862,6602,6362,6092,5862,5632,5332,5032,467
Shares Outstanding0.2%167167166166164164163162162161160160---------
Float-------4,838---3,918---3,058---3,508--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations7.6%107,23799,708215,710-21,3021,047625-2,30621,67831,02182,77733,063-45,14667,34360,203-4,432-40,27242,07030,972-23,17722,21260,513
  Share Based Compensation8.1%25,84323,91528,50422,64326,48326,05123,37718,34319,01925,60027,55215,45124,88522,62022,84619,81321,38726,72928,24524,61629,314
Cashflow From Investing82.4%-20,982-119,359120,84872,85027,7408,898-40,538-60,641-742-31,7073,977-37,732-35,097-8,22714,35117,492-101,47131,594-7,253-64,703-7,803
Cashflow From Financing-17745.0%-276,4971,5677,836-22,620-271-21214,933-16,024-3,1791,03316,27314,945-151-1123,016-4,9241,7462,9061,150963-1,989

ALKS Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
REVENUES:   
Total revenues$ 1,663,405$ 1,111,795$ 1,173,751
EXPENSES:   
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)253,037218,068197,323
Research and development270,806272,702290,924
Selling, general and administrative689,751590,751549,610
Amortization of acquired intangible assets35,68936,36338,148
Total expenses1,249,2831,117,8841,076,005
OPERATING INCOME (LOSS)414,122(6,089)97,746
OTHER INCOME (EXPENSE), NET:   
Interest income30,8547,6292,408
Interest expense(23,032)(13,040)(11,219)
Change in the fair value of contingent consideration (21,750)(1,427)
Other (expense) income, net(425)2,122219
Total other income (expense), net7,397(25,039)(10,019)
INCOME (LOSS) BEFORE INCOME TAXES421,519(31,128)87,727
INCOME TAX (BENEFIT) PROVISION(97,638)2,02411,326
NET INCOME (LOSS) FROM CONTINUING OPERATIONS519,157(33,152)76,401
DISCONTINUED OPERATIONS, NET OF TAX(163,400)(125,115)(124,570)
NET INCOME (LOSS)$ 355,757$ (158,267)$ (48,169)
EARNINGS (LOSS) PER ORDINARY SHARE:   
Earnings (loss) per share from continuing operations - basic$ 3.12$ (0.2)$ 0.47
Earnings (loss) per share from discontinued operations - basic(0.98)(0.76)(0.77)
Earnings (loss) per share - basic2.14(0.97)(0.3)
Earnings (loss) per share from continuing operations - diluted3.06(0.2)0.46
Earnings (loss) per share from discontinued operations - diluted(0.96)(0.76)(0.76)
Earnings (loss) per share - diluted$ 2.1$ (0.97)$ (0.29)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:   
Basic166,223163,742160,942
Diluted169,730163,742164,753
COMPREHENSIVE INCOME (LOSS):   
Net Income (Loss)$ 355,757$ (158,267)$ (48,169)
Holding gain (loss), net of a tax provision (benefit) of $1,195, $(973) and $(706), respectively7,779(7,166)(2,374)
COMPREHENSIVE INCOME (LOSS)363,536(165,433)(50,543)
Product sales, net   
REVENUES:   
Total revenues919,998777,552627,424
Manufacturing and royalty revenues   
REVENUES:   
Total revenues743,388331,983541,807
License revenue   
REVENUES:   
Total revenues 2,0003,500
Research and development revenue   
REVENUES:   
Total revenues$ 19$ 260$ 1,020

ALKS Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 457,469$ 292,473
Receivables, net332,477287,967
Investments—short-term316,022315,992
Inventory186,406181,418
Contract assets7068,929
Prepaid expenses and other current assets98,16641,203
Assets related to discontinued operations 2,324
Assets held for sale94,260 
Total current assets1,485,5061,130,306
PROPERTY, PLANT AND EQUIPMENT, NET226,943222,919
INVESTMENTS—LONG-TERM39,887131,610
RIGHT-OF-USE ASSETS91,46097,539
ASSETS RELATED TO DISCONTINUED OPERATIONS-LONG-TERM 37,763
ASSETS HELD FOR SALE-LONG-TERM 93,871
INTANGIBLE ASSETS, NET1,99137,680
GOODWILL83,02783,027
DEFERRED TAX ASSETS195,888114,572
OTHER ASSETS11,52114,691
TOTAL ASSETS2,136,2231,963,978
CURRENT LIABILITIES:  
Accounts payable and accrued expenses240,561220,089
Accrued sales discounts, allowances and reserves263,641252,115
Operating lease liabilities—short-term5,7469,878
Contract liabilities—short-term2,7306,816
Current portion of long-term debt3,0003,000
Liabilities related to discontinued operations4,5425,844
Total current liabilities520,220497,742
LONG-TERM DEBT287,730290,270
OPERATING LEASE LIABILITIES—LONG-TERM75,70976,287
LIABILITIES RELATED TO DISCONTINUED OPERATIONS-LONG-TERM 13,542
OTHER LONG-TERM LIABILITIES49,87842,384
Total liabilities933,537920,225
COMMITMENTS AND CONTINGENT LIABILITIES (Note 19)
SHAREHOLDERS’ EQUITY:  
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022, respectively
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 172,569,051 and 168,951,193 shares issued; 166,979,833 and 164,377,009 shares outstanding at December 31, 2023 and 2022, respectively1,7261,690
Treasury shares, at cost (5,589,218 and 4,574,184 shares at December 31, 2023 and 2022, respectively)(189,336)(160,862)
Additional paid-in capital2,736,9342,913,099
Accumulated other comprehensive loss(3,110)(10,889)
Accumulated deficit(1,343,528)(1,699,285)
Total shareholders’ equity1,202,6861,043,753
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$ 2,136,223$ 1,963,978
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEwww.alkermes.com
 EMPLOYEES2280

Alkermes PLC Frequently Asked Questions


What is the ticker symbol for Alkermes PLC? What does ALKS stand for in stocks?

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alkermes PLC (ALKS)?

As of Thu Feb 22 2024, market cap of Alkermes PLC is 4.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers. The fair value of Alkermes PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alkermes PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALKS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alkermes PLC a good stock to buy?

The fair value guage provides a quick view whether ALKS is over valued or under valued. Whether Alkermes PLC is cheap or expensive depends on the assumptions which impact Alkermes PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALKS.

What is Alkermes PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ALKS's PE ratio (Price to Earnings) is 13.58 and Price to Sales (PS) ratio is 2.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alkermes PLC's stock?

In the past 10 years, Alkermes PLC has provided -0.046 (multiply by 100 for percentage) rate of return.